216 related articles for article (PubMed ID: 37813880)
1. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.
Hodgson K; Orozco-Moreno M; Scott E; Garnham R; Livermore K; Thomas H; Zhou Y; He J; Bermudez A; Garcia Marques FJ; Bastian K; Hysenaj G; Archer Goode E; Heer R; Pitteri S; Wang N; Elliott DJ; Munkley J
Sci Rep; 2023 Oct; 13(1):17031. PubMed ID: 37813880
[TBL] [Abstract][Full Text] [Related]
2. [Development and Clinical Application of Glycan-Targeted Biomarkers for Prostate Cancer].
Ohyama C; Yoneyama T; Tobisawa Y; Ishikawa T; Hatakeyama S; Koie T; Mori K
Rinsho Byori; 2017 Feb; 65(2):210-217. PubMed ID: 30762989
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Scott E; Hodgson K; Calle B; Turner H; Cheung K; Bermudez A; Marques FJG; Pye H; Yo EC; Islam K; Oo HZ; McClurg UL; Wilson L; Thomas H; Frame FM; Orozco-Moreno M; Bastian K; Arredondo HM; Roustan C; Gray MA; Kelly L; Tolson A; Mellor E; Hysenaj G; Goode EA; Garnham R; Duxfield A; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Singh S; Johnston EW; Punwani S; Knight B; McCullagh P; McGrath J; Crundwell M; Harries L; Bogdan D; Westaby D; Fowler G; Flohr P; Yuan W; Sharp A; de Bono J; Maitland NJ; Wisnovsky S; Bertozzi CR; Heer R; Guerrero RH; Daugaard M; Leivo J; Whitaker H; Pitteri S; Wang N; Elliott DJ; Schumann B; Munkley J
Oncogene; 2023 Mar; 42(12):926-937. PubMed ID: 36725887
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.
Chen Z; Gulzar ZG; St Hill CA; Walcheck B; Brooks JD
Prostate; 2014 Jul; 74(10):1059-67. PubMed ID: 24854630
[TBL] [Abstract][Full Text] [Related]
5. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott E; Archer Goode E; Garnham R; Hodgson K; Orozco-Moreno M; Turner H; Livermore K; Putri Nangkana K; Frame FM; Bermudez A; Jose Garcia Marques F; McClurg UL; Wilson L; Thomas H; Buskin A; Hepburn A; Duxfield A; Bastian K; Pye H; Arredondo HM; Hysenaj G; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Singh S; Johnston EW; Punwani S; Knight B; McCullagh P; McGrath J; Crundwell M; Harries L; Heer R; Maitland NJ; Whitaker H; Pitteri S; Troyer DA; Wang N; Elliott DJ; Drake RR; Munkley J
J Pathol; 2023 Sep; 261(1):71-84. PubMed ID: 37550801
[TBL] [Abstract][Full Text] [Related]
6. Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness.
Sato T; Yoneyama T; Tobisawa Y; Hatakeyama S; Yamamoto H; Kojima Y; Mikami J; Mori K; Hashimoto Y; Koie T; Ohyama C
Biochem Biophys Res Commun; 2016 Jan; 470(1):150-156. PubMed ID: 26768364
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation is a global target for androgen control in prostate cancer cells.
Munkley J
Endocr Relat Cancer; 2017 Mar; 24(3):R49-R64. PubMed ID: 28159857
[TBL] [Abstract][Full Text] [Related]
8. Detection of Core2 β-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer.
Kojima Y; Yoneyama T; Hatakeyama S; Mikami J; Sato T; Mori K; Hashimoto Y; Koie T; Ohyama C; Fukuda M; Tobisawa Y
PLoS One; 2015; 10(9):e0138520. PubMed ID: 26390303
[TBL] [Abstract][Full Text] [Related]
9. The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression.
Kawahara R; Recuero S; Srougi M; Leite KRM; Thaysen-Andersen M; Palmisano G
Mol Cell Proteomics; 2021; 20():100026. PubMed ID: 33127837
[TBL] [Abstract][Full Text] [Related]
10. Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
Tsai CH; Tzeng SF; Chao TK; Tsai CY; Yang YC; Lee MT; Hwang JJ; Chou YC; Tsai MH; Cha TL; Hsiao PW
Cancer Res; 2016 Oct; 76(19):5756-5767. PubMed ID: 27485450
[TBL] [Abstract][Full Text] [Related]
11. Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans.
Giovannone N; Antonopoulos A; Liang J; Geddes Sweeney J; Kudelka MR; King SL; Lee GS; Cummings RD; Dell A; Barthel SR; Widlund HR; Haslam SM; Dimitroff CJ
Front Immunol; 2018; 9():2857. PubMed ID: 30619255
[TBL] [Abstract][Full Text] [Related]
12. The role of glycans in the development and progression of prostate cancer.
Munkley J; Mills IG; Elliott DJ
Nat Rev Urol; 2016 Jun; 13(6):324-33. PubMed ID: 27091662
[TBL] [Abstract][Full Text] [Related]
13. Glycans as Biomarkers in Prostate Cancer.
Scott E; Munkley J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893936
[TBL] [Abstract][Full Text] [Related]
14. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.
Orozco-Moreno M; Visser EA; Hodgson K; Hipgrave Ederveen AL; Bastian K; Goode EA; Öztürk Ö; Pijnenborg JFA; Eerden N; Moons SJ; Rossing E; Wang N; de Haan N; Büll C; Boltje TJ; Munkley J
Glycobiology; 2023 Dec; 33(12):1155-1171. PubMed ID: 37847613
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects.
Fujimura T; Shinohara Y; Tissot B; Pang PC; Kurogochi M; Saito S; Arai Y; Sadilek M; Murayama K; Dell A; Nishimura S; Hakomori SI
Int J Cancer; 2008 Jan; 122(1):39-49. PubMed ID: 17803183
[TBL] [Abstract][Full Text] [Related]
16.
Conroy LR; Stanback AE; Young LEA; Clarke HA; Austin GL; Liu J; Allison DB; Sun RC
Mol Cancer Res; 2021 Oct; 19(10):1727-1738. PubMed ID: 34131069
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation products in prostate diseases.
Dos Santos Silva PM; Albuquerque PBS; de Oliveira WF; Coelho LCBB; Dos Santos Correia MT
Clin Chim Acta; 2019 Nov; 498():52-61. PubMed ID: 31400314
[TBL] [Abstract][Full Text] [Related]
18. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.
Nyalwidhe JO; Betesh LR; Powers TW; Jones EE; White KY; Burch TC; Brooks J; Watson MT; Lance RS; Troyer DA; Semmes OJ; Mehta A; Drake RR
Proteomics Clin Appl; 2013 Oct; 7(9-10):677-89. PubMed ID: 23775902
[TBL] [Abstract][Full Text] [Related]
19. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
20. Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone.
Hodgson K; Orozco-Moreno M; Goode EA; Fisher M; Garnham R; Beatson R; Turner H; Livermore K; Zhou Y; Wilson L; Visser EA; Pijnenborg JF; Eerden N; Moons SJ; Rossing E; Hysenaj G; Krishna R; Peng Z; Nangkana KP; Schmidt EN; Duxfield A; Dennis EP; Heer R; Lawson MA; Macauley M; Elliott DJ; Büll C; Scott E; Boltje TJ; Drake RR; Wang N; Munkley J
EBioMedicine; 2024 May; 104():105163. PubMed ID: 38772281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
